Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Centogene NV's annualizedNet Income for the quarter that ended in Dec. 2023 was $-24.16 Mil. Centogene NV's average total tangible assets for the quarter that ended in Dec. 2023 was $72.85 Mil. Therefore, Centogene NV's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -33.16%.
The historical rank and industry rank for Centogene NV's Return-on-Tangible-Asset or its related term are showing as below:
CNTGF's Return-on-Tangible-Asset is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -2.4 * Ranked among companies with meaningful Return-on-Tangible-Asset only.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Centogene NV Return-on-Tangible-Asset Related Terms
Centogene NV Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Centogene NV's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTGF vs ISPC, CHEK, FUNI: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Centogene NV's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centogene NV Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Centogene NV's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2023) net income data.
What does a Return-on-Tangible-Asset of -33.16% mean?
Centogene NV (CNTGF) has a Return-on-Tangible-Asset of -33.16% as of Dec. 2023. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Centogene NV and its competitors.
Is Centogene NV's Return-on-Tangible-Asset too high?
Centogene NV's current Return-on-Tangible-Asset is -33.16%. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's Return-on-Tangible-Asset compare to ISPC and CHEK?
Centogene NV's Return-on-Tangible-Asset of -33.16% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Centogene NV and its competitors. Centogene NV's current Return-on-Tangible-Asset is -33.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current Return-on-Tangible-Asset of -33.16%. The current Return-on-Tangible-Asset is -33.16%. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Centogene NV (CNTGF), the current Return-on-Tangible-Asset is -33.16% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score
Get the complete analysis for CNTGF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTGF has been successfully added to your 
